Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.

This review discusses polycystic ovary syndrome's metabolic and reproductive impacts, highlighting its insulin resistance and related complications, but reports no new research findings, underscoring the need for lifestyle modifications.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

The researchers reported that a novel family of butyric acid prodrugs, including AN-9 and AN-10, showed potential for anticancer activity, hemoglobin expression induction, and hair follicle protection, with AN-9 in phase II trials.

In this retrospective cohort study, 53.8% of adult rosacea patients who started CGRP monoclonal antibodies for migraines experienced improvement in papules/pustules and erythema/flushing, although moderate adverse events were noted, suggesting these antibodies may benefit rosacea symptoms.

This case report describes a 19-year-old patient with microsatellite stable adrenocortical carcinoma who showed a promising 36-month response to pembrolizumab, including structural and biochemical improvements, with primary adrenal insufficiency as a major side effect.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

In this review, the authors detailed various dermatologic adverse events associated with aromatase inhibitors in postmenopausal women and discussed strategies to potentially prevent these events, aiming to minimize interruptions in breast cancer treatment.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This review discusses potential agents, including acetyl-L-carnitine and vitamins, for repurposing in managing chemotherapy-induced peripheral neuropathy and reports no clinical results; the authors emphasize the need for further research.

This case report describes the management of PRIDE complex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.

This review discusses the effects of valproic acid on immune cell activation and gene expression, potentially influencing infection outcomes and suggesting its promise for autoimmune and hypersensitivity condition management.

This report documents the successful use of theophylline in treating an 11-year-old girl with a rare immunodeficiency syndrome, suggesting potential in drug repurposing for primary immunodeficiency disorders and asthma.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

PRAME helps distinguish between benign and malignant skin cells in most cases.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

These guidelines discuss prevention and management strategies for dermatological toxicities but report no new clinical results; they include expert recommendations for conditions like acneiform rash and hand-foot syndrome.

This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.

This review discusses managing common and notable adverse events associated with the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-positive unresectable/metastatic breast cancer and reports no new clinical results.